乳腺癌中DLC1和DLC1-mRNA的表达及其临床意义

Expression of DLC1 Protein and DLC1-mRNA in Breast Carcinoma and Their Clinical Significance

目的：探讨乳腺癌中肝癌缺失基因1（deleted in liver Cancer-1，DLC1）和DLC1-mRNA的表达及其临床意义。方法：应用原位杂交技术和免疫组织化学EnVision二步法，检测52例乳腺浸润性导管癌和42例非癌乳腺组织（包括癌旁乳腺组织20例和乳腺纤维腺瘤22例）中DLC1和DLC1-mRNA的表达，分析乳腺癌中DLC1和DLC1-mRNA的表达与患者年龄、肿瘤最大直径、组织学分级、腋窝淋巴结转移和TNM分期等临床病理参数的相关性。结果：DLC1和DLC1-mRNA在乳腺癌和非癌乳腺组织中的阳性表达率分别为（57．7％，50．0％）和（92．9％，90．5％），DLC1和DLC1-mRNA在乳腺癌中的表达率显著低于非癌乳腺组织（χ^2=14．717，P=0．000；χ^2=17．518，P=0．000），差异均有显著统计学意义（P〈0．001）。乳腺癌中DLCI和DLC1-mRNA的表达与组织学分级（L=-0．811，P=0．000；rs=-0．422，P〈0．05）、腋淋巴结转移（rs=0．410，P〈0．01；rs=-0．445，P〈0．01）和TNM分期（rs=-0．319，P〈0．05；rs=-0．405，P〈0．05）均呈负相关；DLCI—mRNA的表达与肿瘤最大直径（rs=-0．347，P〈0．05）亦呈负相关。DLC1与肿瘤最大直径（rs=0．073）和DLC1、DLC1-mRNA的表达与患者年龄（rs=0．077；rs=0．008）的相关性均无统计学意义（P〉0．05）。结论：DLC1蛋白和DLC1-mRNA在乳腺癌中呈低表达或失表达，在乳腺癌的恶性演进中扮演着重要角色。检测乳腺癌中DLC1和DLC1-mRNA的表达，结合相关临床病理参数，可作为判断乳腺癌生物学行为和预后的一个参考指标。

Objective： To investigate the expression of DLC1 and DLC1-mRNA and the correlation between these and cancerous and non-cancerous tissue of the breast. Methods： EnVision immunohistochemical method and in situ hybridization were used to detect the expression of DLC1 protein and DLC1 mRNA in 52 invasive breast ductal carcinomas and 42 non-cancerous mammary tissue samples, including 20 paracancerous mammary tissue samples and 22 mammary fibroadenomas. The correlations between the expression of DLC1 and DLC1-mRNA in the breast carcinomas and clinicopathological parameters including patient age, maximum tumor size, tumor histological grade, axillary lymph node metastasis and TNM stage were analyzed. Results： The positive expression rates of DLC1-mRNA and DLC1 protein in the breast carcinomas and non-cancerous breast tissue were （57.7%, 50.0%） and （92.9%, 90.5%）, respectively. The positive expression rates of DLC1 and DLC1-mRNA were significantly lower in breast carcinomas than in non-cancerous mammary tissue （χ^2= 14.717, P=0.000; χ^2=17.518, P=-0.000）. All the differences between the 2 groups had statistical significance （P〈0.001）. Correlation analysis showed that the expression of DLC1 protein and DLC1-mRNA in invasive breast ductal carcinomas were negatively correlated to tumor histological grade （rs=-0.811, P=0.000; r,=-0.422, P〈0.05）, axillary lymph node metastasis （r,=-0.410, P〈0.01; rs=-0.445, P〈0.01） and TNM stage （rs=-0.319, P〈0.05; ro=-0.405, P〈0.05）. The expression of DLC1-mRNA in invasive ductal breast carcinomas was negatively correlated with tumor size （rs=-0.347, P〈0.05）. There was no significant correlation between the positive expression rate of DLC1 and tumor size （rs=0.073, P〉0.05）. There were no significant correlations between the positive expression rates of DLCland DLC1-mRNA and patient age （rs=0.077; rs= 0.008;P〉0.05 ）. Conclusion： Lower or no expression of DLC1 and DLC1-mRNA may play an important role in malignant progression in breast carcinoma. Combining related clinicopathological parameters with detection of the expression of DLC1 and DLC1-mRNA may be useful parameters for evaluating the biological behavior and the prognosis of breast carcinoma.